STRONG RESULTS FOR NAO.VNS™ FIRST-IN-HUMAN STUDY
Strong safety, robust device performance, and positive patient outcomes
Synergia Medical revolutionary technology
Synergia Medical will revolutionizes neuromodulation with optoelectronic technology, offering:
Full MRI compatibility – Low restrictions on MRI scans (100–150M annually worldwide), eliminating patient care limitations and burdens. Full activity during imaging enables physicians to adjust therapy in real time while observing brain responses—an approach many neurologists believe could enhance VNS efficacy.
EMI immunity – Groundbreaking protection against widely used medical EMI sources such as electrosurgery (utilized in 80% of surgeries) and defibrillators, ensuring greater safety in patient care.
Extended battery life & fast recharging – EMI-related power inefficiencies are eliminated, allowing for a rapid recharge—just 1 minute daily—for an expected long-term battery lifetime of 15 years. This significantly reduces replacement surgeries and supports energy-intensive stimulation modes that could enhance therapy.
Enhanced cybersecurity – Closed-loop optical communication minimizes exposure to external and remote hacking, providing a highly secure system.
News and Events
- February 25 2025 SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS™ FIRST-IN-HUMAN STUDY
- January 13 2025 SYNERGIA MEDICAL ANNOUNCES: FIVE PATIENTS NOW IMPLANTED WITH NAO.VNS™ LEADERSHIP CHANGE: CHARLES NOLET TO SUCCEED ATTILA BORBATH AS CEO
- September 23 2024 SYNERGIA MEDICAL SUCCESSFULLY IMPLANTS FIRST PATIENTS WITH NAO.VNS™
SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS™ FIRST-IN-HUMAN STUDY
Brussels, February 24, 2025 – Synergia Medical announces that its NAO.VNS™ device, successfully implanted in five patients at UZ Gent and Cliniques universitaires Saint-Luc in Belgium, has met the primary safety endpoint in the AURORA first-in-human clinical study. Synergia Medical's technology is a next-generation neuromodulation platform that eliminates the main metal components of traditional devices, ensuring immunity to electromagnetic interference (EMI).
SYNERGIA MEDICAL ANNOUNCES: FIVE PATIENTS NOW IMPLANTED WITH NAO.VNS™ LEADERSHIP CHANGE: CHARLES NOLET TO SUCCEED ATTILA BORBATH AS CEO
Brussels, January 13, 2025. Synergia Medical SA, a leader in developing optoelectronic medical devices, is pleased to announce the successful implantation of its groundbreaking NAO.VNSTM system in three more patients, bringing the total to five, as part of the AURORA study. These First-In-Human implantations took place at Cliniques Universitaires Saint-Luc and UZ Gent, Belgium. All patients have fully recovered, allowing the initiation of stimulation therapy as planned.
SYNERGIA MEDICAL SUCCESSFULLY IMPLANTS FIRST PATIENTS WITH NAO.VNS™
Brussels, 23 September 2024 – Synergia Medical, a leader in the development of optoelectronic medical devices, is pleased to announce the successful implantation of its groundbreaking NAO.VNS system in the first two patients as part of the AURORA study. These first-in-human implantations took place on September 6, 2024, at Cliniques Universitaires Saint-Luc and UZ Gent. Two weeks after surgery, both patients have fully recovered, allowing the initiation of stimulation therapy as planned.